NASDAQ · IVVDHealthcareBiotechnology

Invivyd financials

$0.8501−10.52%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
Revenue$53.4M$25.4M$0.00$0.00
Gross profit$49.7M$23.8M$0.00$0.00
Gross margin93.0%93.6%——
Operating income-$55.6M-$176.9M-$212.8M-$230.7M
Net income-$52.5M-$169.9M-$198.6M-$241.3M
Net margin−98.2%−669.4%——
Diluted EPS$-0.30$-1.43$-1.81$-2.23
EBITDA-$54.8M-$175.4M-$212.3M-$230.2M
Operating cash flow-$58.1M-$170.5M-$173.2M-$220.0M
Free cash flow-$58.3M-$170.6M-$173.8M-$221.7M
Diluted shares172.2M118.6M109.5M108.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31
Cash & equivalents$226.7M$69.3M$200.6M$92.1M
Short-term investments$0.00$0.00$0.00$279.9M
Total debt$0.00$0.00$0.00$0.00
Total assets$276.9M$129.5M$229.2M$383.2M
Total liabilities$35.3M$62.0M$51.7M$27.2M
Shareholders' equity$241.5M$67.5M$177.5M$356.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology